Drug Profile
Denosumab biosimilar - Outlook Therapeutics
Alternative Names: ONO4010; ONS-4010Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Outlook Therapeutics
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bone cancer; Bone disorders; Bone metastases; Breast cancer; Male osteoporosis; Malignant hypercalcaemia; Multiple myeloma; Non-small cell lung cancer; Osteogenesis imperfecta; Osteoporosis; Postmenopausal osteoporosis; Rheumatoid arthritis
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Bone cancer in USA (SC) (Outlook Therapeutics pipeline, August 2023)
- 24 Aug 2023 Discontinued - Preclinical for Bone disorders in USA (SC) (Outlook Therapeutics pipeline, August 2023)
- 24 Aug 2023 Discontinued - Preclinical for Bone metastases in USA (SC) (Outlook Therapeutics pipeline, August 2023)